Catalyst stock: buy or sell?
September 20th, 2019
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases.
Should I buy Catalyst stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading strategy that matches with your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Catalyst Pharmaceuticals stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Catalyst stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 2 ratings published for CPRX stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
Catalyst stock analysis
Catalyst Pharmaceuticals shares stepped up 0.76% to $6.62 today.
On September 11th, CPRX hit new all time highs, pushing higher previous ATH of $7.43 recorded . New ATHs are usual entry points for many trading setups as there aren't higher resistences. Catalyst Pharmaceuticals closed today at $6.62 and stepped up a slightly fine 0.76%. On June CPRX price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. Since last August/22 when SMA50d and SMA100d crossed up, CPRX price gained $0.35 per share (5.58%).
After sliding a spooky -6.28% in a week last week, Catalyst Pharmaceuticals closed this week at $6.62 and boosted an astounding 6.60%.
Not so far away is the last all-time high Catalyst marked last week. Catalyst stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since mid May when CPRX stock price broke up the SMA40w line, it gained $3.48 (110.83%). Since SMA20d and SMA40w crossed up by mid April, CPRX price climbed $1.23 per share (22.82%).
Catalyst stock price history
Catalyst IPO was on November 8th, 2006 at $6.00 per share1. Since then, CPRX stock grew a 10.30%, with an average of 0.90% per year. If you had invested right after CPRX's IPO a $1,000 in Catalyst stock in 2006, it would worth $103.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Catalyst stock historical price chart
CPRX stock reached all-time highs on Sep/11 with a price of $7.67.
Catalyst stock price target is $10.00Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. Currently, only 1 price prediction for Catalyst stock was posted in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Catalyst reported its latest financial data, posting a more than good gain for the Earnings per Share (EPS) ratio. Experts were expecting $-0.12 per share, but Catalyst Pharmaceuticals posted $-0.14.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Catalyst annual turnover to $0.50 M dollars from marked in . , its earnings margin (compared to revenues) to -6,800.70%, that is $-34.00 million.
|2018||$0.50 M||-||$-34.00 M-6800.7%||-|
Quarterly financial resultsCatalyst reported $0.50 million in revenues for 2018-Q4, a inf% up compared to previous quarter. Reported quarter earnings marked $-14.50 million with a profit margin of -2,899.92%. Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, Catalyst Pharmaceuticals sales marked an extraordinary increase and climbed a inf%.
|2018-Q4||$0.50 M||-||$-14.50 M-2899.9%||-|
Catalyst ownershipWhen you are planning to invest in a stock, it's worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Catalyst, 6.89% of all outstanding shares are owned by its staff.
In case of Catalyst Pharmaceuticals stock, 52.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CPRX stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Catalyst:
|Market cap||$681.4 M||$147.9 B||$167.9 M||$13.5 B||$343.5 B|
|Total shares||102.9 M||1,770.0 M||48.1 M||179.5 M||2,640.0 M|
|Float shares||77.9 M||1,750.0 M||39.5 M||178.3 M||2,630.0 M|
|- Institutional holdings (%)||52.0%||76.5%||112.3%||102.9%||69.2%|
|- Insider holdings (%)||6.9%||0.7%||1.8%||0.4%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$6.48 - $6.72|
|Average true range||$0.53|
|50d mov avg||$5.53|
|100d mov avg||$4.67|
|200d mov avg||$4.00|
Catalyst performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Catalyst, the comparison is made against , Acorda Therapeutics, BioMarin Pharmaceutical, , Pfizer and Sarepta Therapeutics.